文献速递眼底病与葡萄膜炎

Janus激酶抑制剂治疗与自身免疫性疾病患者年龄相关性黄斑变性风险

Janus Kinase Inhibitor Therapy and Risk of Age-Related Macular Degeneration in Autoimmune Disease.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

这项回顾性观察性队列研究利用美国行政索赔数据库(2010年1月1日至2022年1月31日),将接受JAKi治疗的自身免疫性疾病患者与接受非JAKi免疫治疗者按1:1倾向评分匹配,发现JAKi治疗6个月以上与AMD发生率相对降低49%(MarketScan)和73%(Optum)相关,绝对百分比降低分别为0.36%和0.32%,作者认为JAKi使用可能与AMD风险降低相关。

要点

  • 在MarketScan数据库中,JAKi组AMD发生10/9126例,非JAKi组43/9126例,调整后发病率比0.51(95%CI 0.19-0.90)。
  • 在Optum数据库中,JAKi组AMD发生3/5667例,非JAKi组21/5667例,调整后发病率比0.27(95%CI 0.03-0.74)。
  • 绝对百分比降低分别为0.36%(MarketScan)和0.32%(Optum),有利于JAKi组。

核心结论

  • JAKi使用可能与患有主要自身免疫性疾病的美国成人新发AMD风险降低相关。
  • 绝对百分比降低与JAKi在该人群中的潜在作用一致。
  • 作者建议未来进行长期随访研究,以探讨JAKi使用与其他疾病适应症中新发AMD的关联。
  • 研究系统炎症和JAK-信号转导及转录激活因子信号在AMD中的作用可能有助于理解AMD病理生理并带来新的治疗选择。

研究设计与样本

  • 回顾性观察性队列研究,使用Merative MarketScan研究数据库(Commercial和Medicare Supplemental)和Optum Clinformatics Data Mart数据库2010年1月1日至2022年1月31日的行政索赔数据。
  • 接受JAKi治疗的自身免疫性疾病患者(MarketScan 9126例,Optum 5667例)按1:1倾向评分匹配至相同数量的接受非JAKi免疫治疗的研究合格患者。
  • 暴露定义为治疗持续时间6个月或更长。
  • 主要结局为治疗最初6至18个月内的AMD(渗出性和非渗出性)发生率,使用贝叶斯泊松回归模型估计发病率比、95%CI和AMD后验概率。

主要发现

  • 匹配后,JAKi患者人群中女性在MarketScan和Optum分别占14 019/18 252(76.6%)和8563/3364(75.2%)。
  • 两个队列中超过60%的患者年龄大于55岁。
  • 在指定治疗期间,MarketScan中JAKi组AMD发生10/9126例(调整后发病率比0.51;95%CI 0.19-0.90),非JAKi组43/9126例(调整后发病率比1[参照]),相对降低49%。
  • 在Optum中JAKi组AMD发生3/5667例(调整后发病率比0.27;95%CI 0.03-0.74),非JAKi组21/5667例(调整后发病率比1[参照]),相对降低73%。
  • 绝对百分比降低分别为0.36%(MarketScan)和0.32%(Optum),有利于JAKi组;调整后风险小于1的后验概率分别为97.6%(MarketScan)和98.9%(Optum)。

关键数值与推荐

  • MarketScan:JAKi组AMD发生10/9126例,调整后发病率比0.51(95%CI 0.19-0.90);非JAKi组43/9126例,调整后发病率比1(参照)。
  • Optum:JAKi组AMD发生3/5667例,调整后发病率比0.27(95%CI 0.03-0.74);非JAKi组21/5667例,调整后发病率比1(参照)。
  • 绝对百分比降低:MarketScan 0.36%,Optum 0.32%,均有利于JAKi组。
  • 调整后风险小于1的后验概率:MarketScan 97.6%,Optum 98.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者建议未来进行长期随访研究,以探讨JAKi使用与其他疾病适应症中新发AMD的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The involvement of chronic inflammation in the pathogenesis of age-related macular degeneration (AMD) opens therapeutic possibilities to AMD management. OBJECTIVE: To determine whether Janus kinase inhibitors (JAKis) are associated with a reduced risk of AMD development in patients with autoimmune diseases. DESIGN, SETTING, AND PARTICIPANTS: This retrospective observational cohort study used administrative claims data from Merative MarketScan research databases (Commercial and Medicare Supplemental) and Optum Clinformatics Data Mart databases between January 1, 2010, and January 31, 2022. Patients with autoimmune diseases satisfying study eligibility criteria and who received JAKi treatment (9126 in MarketScan and 5667 in Optum) were propensity score matched (1:1) to identical numbers of study-eligible patients who received non-JAKi-based immunotherapy. EXPOSURE: Treatment duration of 6 months or longer. MAIN OUTCOMES AND MEASURES: Incidence rates of AMD (exudative and nonexudative) over the first 6 to 18 months of treatment were determined, and bayesian Poisson regression models were used to estimate incidence rate ratios, 95% CIs, and posterior probabilities of AMD. RESULTS: After matching, female sex represented the majority of the patient population in both MarketScan and Optum (14 019/18 252 [76.6%] and 8563/3364 [75.2%], respectively in the JAKi patient population). More than 60% of the patient population was older than 55 years of age in both cohorts. Over the specified treatment period, a 49% relative reduction in incidence of AMD was observed among patients who received JAKi therapy (10/9126 events; adjusted incidence rate ratio [AIRR], 0.51; 95% CI, 0.19-0.90) vs those who received non-JAKi therapy (43/9126 events; AIRR, 1 [reference]) in MarketScan, and a 73% relative reduction in incidence of AMD was observed among patients who received JAKi therapy (3/5667 events; AIRR, 0.27; 95% CI, 0.03-0.74) vs those who received non-JAKi therapy (21/5667 events; AIRR, 1 [reference]) in Optum. The absolute percentage reductions were 0.36% (MarketScan) and 0.32% (Optum), favoring patients who received JAKi therapy. Posterior probabilities of the adjusted risk being less than unity were 97.6% (MarketScan) and 98.9% (Optum) for those who received JAKi therapy vs those who received non-JAKi therapy in MarketScan and Optum, respectively. CONCLUSIONS AND RELEVANCE: JAKi use may be associated with a reduced risk of incident AMD in US adults with major autoimmune diseases. The absolute percentage reduction is consistent with a potential role for JAKi in this population. Future studies with long-term follow-up are recommended to investigate the association between JAKi use and incident AMD in other disease indications. Investigation into the role of systemic inflammation and JAK-signal transducers and activators of transcription signaling in AMD may improve understanding of the pathophysiology of AMD and lead to new treatment options.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hallak JA, Abbasi A, Goldberg RA, et al. Janus Kinase Inhibitor Therapy and Risk of Age-Related Macular Degeneration in Autoimmune Disease. JAMA Ophthalmol. 2024. PMID: 38990568. doi:10.1001/jamaophthalmol.2024.2376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。